Published in Cancer Weekly, June 18th, 2002
The ongoing phase II clinical trial in recurrent advanced ovarian cancer is a multicenter, open label design, evaluating squalamine in combination with carboplatin. In this study, 35% of evaluable patients (9 of 26) have had an objective response to the study drug regimen of squalamine and carboplatin. Best response to therapy has included five complete responses, and four partial responses. Four of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.